Erratum: Novel evidence‐based colchicine dose‐reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P‐glycoprotein inhibitors; Association of PPP2CA Polymorphisms With Systemic Lupus Erythematosus Susceptibility in Multiple Ethnic Groups
Year: 2011
Type: erratum
Abstract: In Table 4 of the article by Terkeltaub et al in the August 2011 issue of Arthritis & Rheumatism (pages 2226–2237), the colchicine dosing recommendation for acute gout flare with concomitant clarithromycin, ketoconazole, ritonavir (strong CYP34A inhibitor) therapy was incorrectly stated. The dosing recommendation should have read “0.6 mg (1 tablet), 1 dose; followed by 0.3 mg (one-half tablet) 1 hour later; dose to be repeated no earlier than 3 days.” In the article by Tan et al in the September 2011 issue of Arthritis & Rheumatism (pages 2755–2763), the name of an author was omitted: Graciela S. Alarcón, MD, MPH (University of Alabama at Birmingham) should have been listed as an author. Dr. Alarcón participated in acquisition of data for the study, was involved in drafting the article or revising it critically for important intellectual content, and approved the final version to be published. We regret the errors.
Source: Arthritis & Rheumatism
DOI: 10.1002/art.33392
Language: English
Subfield: Pharmacology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W1594050216